Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsNew findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.
A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.
FDA Approves First Dual-Agent Eye Drop for Near Vision Loss
1.
Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.
2.
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
3.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
4.
Team finds broken 'brake' on cancer mutation machine.
5.
Mapping lifelong chronic health risks for childhood cancer survivors
1.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Giant Sebaceous Cyst of the Scalp Mimicking a Soft Tissue Tumor: A Case Study
4.
Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery
5.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge